Primidone Tablets, 50 mg recall — Amneal Pharmaceuticals, LLC (Class III)

Amneal Pharmaceuticals, LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Primidone Tablets, 50 mg — a Class III recall, initiated 2026-06-03 and posted to the FDA enforcement report on 2026-06-17, under recall number D-0585-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.”. From the product description, the form is tablets, the strength given is 50 mg, the package is described as 100 Tablets and it is marked Rx only. 1 National Drug Code number is printed in the record: 53746-544-01. Distribution is recorded as “Nationwide within the USA” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99146. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0585-2026
FDA event ID 99146
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Amneal Pharmaceuticals, LLC
Recall initiated 2026-06-03
Reported by FDA 2026-06-17
Report lag 14 days from initiation to report
Distribution Nationwide within the USA. — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Primidone Tablets, USP, 50 mg, 100 Tablets per Bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad 382213, INDIA. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC: 53746-544-01

Reason reported by FDA

Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.

22 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 34-word product description above; each is a literal substring of it.

Product named Primidone Tablets
Form Tablets
Strength 50 mg
Package 100 Tablets
NDC 53746-544-01
Marketing category Rx only
Manufactured by Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit
Distributed by Amneal Pharmaceuticals LLC, Bridgewater

Other indexed recalls of primidone

6 indexed records name primidone as the recalled substance. Matching is on the product-name prefix of the FDA's own text, so other strengths and packages are included.

Recall recordRecall numberRecalling firmStrength / formReported
Primidone Tablets USP, 250mgD-0533-2026Lannett Company Inc.250mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0534-2026Golden State Medical Supply Inc.50 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0535-2026Golden State Medical Supply Inc.250 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0536-2026Amerisource Health Services LLC250 mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0537-2026Amerisource Health Services LLC50 mg · Tablets2026-05-27

Reported in the same month (2026-06)

74 enforcement reports carry a report date in 2026-06; these 5 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLCClass III2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLCClass III2026-06-10
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz IncClass III2026-06-24
Nicotine Transdermal System Patch, 14 mgD-0550-2026Aveva Drug Delivery Systems, Inc.Class III2026-06-03
PRED MILD, 0.12%D-0551-2026Abbvie Inc.Class III2026-06-03

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 6 nearest to 2026-06-17 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.10 mg/5 mL · Oral Solution2026-07-01
Busulfan Injection, 60 mgD-0539-2026Sagent Pharmaceuticals60 mg · Injection2026-05-27
Fexofenadine Hydrochloride Tablets, 180 mgD-0654-2026Sun Pharmaceutical Industries Inc180 mg · Tablets2026-07-08
busPIRone Hydrochloride Tablets, 5 mgD-0511-2026Unichem Pharmaceuticals Usa Inc.5 mg · Tablets2026-05-13
Levocarnitine Injection, 1 g/5 mLD-0494-2026American Regent, Inc.1 g/5 mL · Injection2026-05-06
Lidocaine Wound Gel, 0.13%D-0509-2026Water-jel Technologies, LLC0.13% · Gel2026-05-06

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 53746-544-01 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Amneal Pharmaceuticals, LLC (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0585-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0585-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-06-17
Ingested
2026-08-22
Record hash
0f2009080f666a36

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.